Clinical trial · Interventional
Early Palliative Care for Patients With Advanced Pancreatic Cancer.
Early Palliative Care for Patients With Advanced Pancreatic Cancer (EarlyCarePan).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic adenocarcinoma is one of the deadliest cancers. Patients with pancreatic cancer experience marked physical suffering, psychological distress and resource-demanding care at the end-of-life. Therefore, an urgent need exists to evaluate the early specialized palliative care model in a comparative study and across multiple care settings to define quality of life and survival benefits in patients with pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Early Palliative Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Early Palliative Care
- description
- Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.
- interventionNames
- Other: Early Palliative Care
- type
- NO_INTERVENTION
- label
- Standard Care Arm
- description
- Palliative care visit only upon request from attending oncologist(s) or patient/family.
Primary outcomes (1)
- measure
- Adjusted mean change in global health status/QoL score at 12 weeks
- timeFrame
- 12 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult males and females (aged 18 and over) * Confirmed by cytology or histology incurable PDAC who are planned to receive medical care for cancer in the first-line setting at the enrolling institution within ≤ 2 weeks * Written informed consent before any study procedures * Performance status: ECOG 0-2 * Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member * Planning to receive all medical care for cancer at the enrolling institution. Exclusion Criteria: * Patients who are already receiving care from the palliative care service are not eligible for participation in the study * Exhibiting signs of overt psychopathology or cognitive dysfunction * Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments * Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.
References
Publications (0)
Data not yet available